Vinati Organics Ltd is preparing for its next growth cycle by expanding beyond its flagship ATBS business. While ATBS continues to remain the company’s largest revenue contributor, management is building multiple growth drivers through new products, downstream integration and capacity additions.
The company reported consolidated revenue of ₹2,280 crore in FY26. EBITDA rose 13 percent year-on-year to ₹707 crore, while profit after tax increased 9 percent to ₹444 crore.
ATBS remains the core business
ATBS contributed around 35 percent of consolidated revenue in FY26.
Demand was affected during part of the year because of inventory destocking, but management said the business has recovered and expects volume growth of 15-20 percent in FY27.
ATBS finds applications across several industries, including:
- Oil and gas.
- Water treatment.
- Mining.
- Detergents.
- Personal care.
- Industrial chemicals.
The company completed the first phase of capacity expansion during FY26, taking ATBS capacity to around 50,000 tonnes.
Expansion plans
- Phase 1 expansion completed in FY26.
- Phase 2 expansion is expected by October 2026.
- Higher utilisation is likely from FY28.
- Current utilisation stands at around 50 percent.
Management expects healthy demand growth to continue over the next three years.
New products may emerge as a key growth driver
Vinati Organics plans to commercialise two to three new specialty chemicals during the second half of FY27.
Meaningful revenue contribution is expected from FY28.
The products are mainly downstream derivatives of existing chemicals and include:
- MEHQ derivatives.
- Butyl phenol derivatives.
- New antioxidants.
These products will target sectors such as:
- Fragrances.
- Personal care.
- Food additives.
- Plastic additives.
Management said the focus remains on niche chemicals with limited competition and higher margins.
The company is also evaluating opportunities in monomers and polymers, although no final decision has been announced.
VOPL project set to become a new revenue source
The company’s wholly owned subsidiary, VOPL, generated only about ₹10 crore of revenue in FY26.
Production was impacted after the plant faced issues related to a new manufacturing process.
Management said process reengineering is expected to be completed by September 2026.
Production is scheduled to resume in October 2026.
Expected contribution
- Revenue target of ₹100-120 crore from Q3 FY27 onward.
- Focus on MEHQ and Guaiacol derivatives.
- Anisole production will also be brought in-house.
Out of the planned ₹200-250 crore FY27 capex, around ₹40-50 crore has been earmarked for VOPL.
Antioxidants business continues to grow
The antioxidants segment recorded 15 percent revenue growth in FY26 despite pricing pressure from Chinese competitors.
The company has reapplied for anti-dumping duty after its earlier application was rejected. A decision could take another six to nine months.
Management expects combined revenues from antioxidants and butyl phenols to reach ₹800-900 crore over the next two years.
Capacity utilisation
- Butyl phenols utilisation currently stands at 70-75 percent.
- Incremental output will mainly be used for captive consumption to support antioxidant growth.
Strong balance sheet supports expansion
Vinati Organics ended FY26 with:
- ₹190 crore in cash and treasury investments.
- Zero debt.
The company plans annual capital expenditure of ₹250-300 crore over the next three to five years.
The investments will be directed towards:
- Capacity expansion.
- Process improvements.
- New product development.
Management said all growth plans will be funded through internal accruals.
Outlook
ATBS continues to provide a stable earnings base for Vinati Organics. At the same time, the company is building additional growth engines through VOPL, antioxidants and a pipeline of downstream specialty chemicals.
If these projects progress as planned, Vinati Organics could evolve into a more diversified specialty chemicals platform over the next three to five years.
TL;DR
Vinati Organics is expanding beyond ATBS through new specialty chemicals, antioxidant growth and the VOPL project. With zero debt and planned annual capex of ₹250-300 crore, management expects multiple growth drivers to emerge over the coming years.
AI Summary
- FY26 revenue stood at ₹2,280 crore and PAT rose to ₹444 crore.
- ATBS capacity has increased to 50,000 tonnes.
- Two to three new specialty chemicals are expected to be commercialised in H2 FY27.
- VOPL is expected to contribute ₹100-120 crore of revenue from Q3 FY27.
- The company ended FY26 with zero debt and ₹190 crore in cash and investments.
